DOCSLIB.ORG

Reference: WLI/100 28 March 2007

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reference: WLI/100 28 March 2007 WORLD TRADE ORGANIZATION ORGANISATION MONDIALE DU COMMERCE ORGANIZACIÓN MUNDIAL DEL COMERCIO Reference: WLI/100 28 March 2007 MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION DONE AT MARRAKESH ON 15 APRIL 1994 GENERAL AGREEMENT ON TARIFFS AND TRADE 1994 CERTIFICATION OF MODIFICATIONS AND RECTIFICATIONS TO SCHEDULE XXXVIII – JAPAN TRANSMISSION OF CERTIFIED TRUE COPY I have the honour to furnish herewith a certified true copy of the Certification of Modifications and Rectifications to Schedule XXXVIII – Japan, effective 14 March 2007. Pascal Lamy Director-General 07-1286 WT/Let/568 Centre William Rappard Rue de Lausanne 154 Case postale CH - 1211 Genève 21 Téléphone: (+41 22) 739 51 11 Fax: (+41 22) 731 42 06 Internet: http://www.wto.org SCHEDULES OF TARIFF CONCESSIONS TO THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994 CERTIFICATION OF MODIFICATIONS AND RECTIFICATIONS, 14 MARCH 2007 SCHEDULE XXXVIII – JAPAN WHEREAS the CONTRACTING PARTIES to the General Agreement on Tariffs and Trade 1947 adopted, on 26 March 1980, a Decision on Procedures for Modification and Rectification of Schedules of Tariff Concessions (BISD 27S/25); WHEREAS in accordance with the provisions of the above-mentioned Decision, the draft containing modifications and rectifications to Schedule XXXVIII – Japan was communicated to all Members in documents G/MA/TAR/RS/114 and was approved on 14 March 2007; IT IS HEREBY CERTIFIED that the modifications and rectifications to Schedule XXXVIII – Japan are established in conformity with the above-mentioned Decision. The annexed modifications and rectifications to the Schedule become effective in accordance with the notification given to that effect by the Government of Japan to the Director-General of the World Trade Organization (hereinafter referred to as the "WTO") upon completion of Japan's internal procedures. This Certification is deposited with the Director-General of the WTO, who shall promptly furnish a certified true copy thereof to each Member of the WTO. It shall be registered in accordance with the provisions of Article 102 of the Charter of the United Nations. DONE at Geneva this fourteenth day of March, two thousand and seven. Pascal Lamy Certified copy: Director-General SCHEDULE XXXVIII – JAPAN 14 March 2007 SCHEDULE XXXVIII – JAPAN PART I MOST-FAVOURED-NATION TARIFF SECTION II Other Products Mark the tariff item numbers 2903.30, 2903.47, 2907.30, 2913.00 and 3504.00 with a letter “P”. 1 Attachment to SCHEDULE XXXVIII – JAPAN Replace “Annexes IA, IB and IC” in category (3) by “Annexes IA, IB, IC and ID”. Replace “Annexes IA, IB and IC” in category (4) by “Annexes IA, IB, IC and ID”, and “Annexes IIA, IIB and IIC” by “Annexes II”. Replace “Annexes IVA, IVB and IVC” in category (6) by “Annexes IVA, IVB, IVC and IVD”. 2 Insert the following Annex after Annex IC Annex I D Designated Pharmaceutical Active Ingredients (Additions by the third review) HS Subheading Description HS Subheading Description 2842.90 vangatalcite 2903.47 perflubrodec 2843.90 eptaplatin 2906.19 becocalcidiol 2843.90 miriplatin 2906.19 inecalcitol 2843.90 padoporfin 2907.30 alfatradiol 2843.90 picoplatin 2909.49 atocalcitol 2843.90 satraplatin 2909.49 fispemifene 2843.90 triplatin tetranitrate 2909.49 ospemifene 2844.40 technetium (99mTc) fanolesomab 2909.50 soneclosan 2844.40 technetium (99mTc) nitridocade 2914.40 irofulven 2844.40 yttrium (90Y) tacatuzumab tetraxetan 2914.70 nebicapone 2845.90 deutolperisone 2915.39 anecortave 2846.90 gadocoletic acid 2915.90 arundic acid 2846.90 gadodenterate 2916.39 bexarotene 2846.90 gadofosveset 2918.19 icomucret 2846.90 gadomelitol 2918.19 tenivastatin 2903.30 perflexane 2918.19 tisocalcitate 2903.30 perflisobutane 2918.90 etalocib 2903.30 perflubutane 2918.90 gemcabene 2903.30 perflutren 2918.90 naveglitazar 3 HS Subheading Description HS Subheading Description 2918.90 tesaglitazar 2922.50 caloxetic acid 2918.90 travoprost 2922.50 desvenlafaxine 2921.30 neramexane 2922.50 etilevodopa 2921.49 cinacalcet 2922.50 fesoterodine 2921.49 delucemine 2922.50 fosveset 2921.49 levmetamfetamine 2922.50 isalmadol 2922.19 edronocaine 2922.50 melevodopa 2922.19 esoxybutynin 2922.50 ritobegron 2922.19 fingolimod 2922.50 solabegron 2922.19 mantabegron 2924.10 carglumic acid 2922.19 squalamine 2924.10 teglicar 2922.19 talibegron 2924.10 valrocemide 2922.19 tesmilifene 2924.29 aliskiren 2922.19 trodusquemine 2924.29 amiglumide 2922.19 xidecaflur 2924.29 arformoterol 2922.29 nolomirole 2924.29 axitirome 2922.29 tapentadol 2924.29 efaproxiral 2922.29 tecalcet 2924.29 frakefamide 2922.30 esketamine 2924.29 iosimenol 2922.49 eglumetad 2924.29 lacosamide 2922.49 icofungipen 2924.29 ladostigil 2922.49 lumiracoxib 2924.29 neboglamine 2922.49 robenacoxib 2924.29 oseltamivir 2922.50 axomadol 2924.29 ralfinamide 4 HS Subheading Description HS Subheading Description 2924.29 safinamide 2929.90 avasimibe 2924.29 salcaprozic acid 2929.90 banoxantrone 2924.29 salclobuzic acid 2929.90 disufenton sodium 2924.29 tabimorelin 2930.90 armodafinil 2924.29 tacedinaline 2930.90 canfosfamide 2924.29 talaglumetad 2930.90 desmeninol 2924.29 taltobulin 2930.90 dextiopronin 2924.29 topilutamide 2930.90 eflucimibe 2924.29 valategrast 2930.90 esonarimod 2925.20 amelubant 2930.90 exisulind 2925.20 anisperimus 2930.90 pemaglitazar 2925.20 delmitide 2930.90 rimeporide 2925.20 olanexidine 2930.90 tanomastat 2925.20 peramivir 2931.00 ibrolipim 2926.90 cilomilast 2931.00 lidadronic acid 2926.90 manitimus 2932.19 milataxel 2926.90 naminidil 2932.19 rostafuroxin 2926.90 teriflunomide 2932.29 alemcinal 2928.00 eplivanserin 2932.29 amotosalen 2928.00 istaroxime 2932.29 ascorbyl gamolenate 2928.00 marimastat 2932.29 disermolide 2928.00 meldonium 2932.29 firocoxib 2928.00 sardomozide 2932.29 fluorescein lisicol 2928.00 semapimod 2932.29 mitemcinal 5 HS Subheading Description HS Subheading Description 2932.29 rofecoxib 2933.29 dapiclermine 2932.29 selamectin 2933.29 dibotermin alfa 2932.99 artemotil 2933.29 doranidazole 2932.99 artenimol 2933.29 emfilermin 2932.99 carabersat 2933.29 enfuvirtide 2932.99 defoslimod 2933.29 eptotermin alfa 2932.99 dexbudesonide 2933.29 exenatide 2932.99 enrasentan 2933.29 fadolmidine 2932.99 escitalopram 2933.29 fampronil 2932.99 fondaparinux sodium 2933.29 fipamezole 2932.99 idraparinux sodium 2933.29 imidafenacin 2932.99 idronoxil 2933.29 lusupultide 2932.99 lirimilast 2933.29 mecasermin rinfabate 2932.99 omigapil 2933.29 olmesartan 2932.99 ortataxel 2933.29 palifermin 2932.99 osemozotan 2933.29 rebimastat 2932.99 oxeglitazar 2933.29 repifermin 2932.99 paclitaxel ceribate 2933.29 semparatide 2932.99 ramelteon 2933.29 tadekinig alfa 2932.99 tidembersat 2933.29 tiplimotide 2932.99 tonabersat 2933.39 adekalant 2933.29 abrineurin 2933.39 alvameline 2933.29 bifarcept 2933.39 alvimopan 2933.29 cipralisant 2933.39 ancriviroc 6 HS Subheading Description HS Subheading Description 2933.39 arimoclomol 2933.39 iferanserin 2933.39 atazanavir 2933.39 ilaprazole 2933.39 bamirastine 2933.39 indibulin 2933.39 barixibat 2933.39 ipravacaine 2933.39 bilastine 2933.39 ispronicline 2933.39 capravirine 2933.39 itriglumide 2933.39 caricotamide 2933.39 iturelix 2933.39 cipemastat 2933.39 lanicemine 2933.39 crobenetine 2933.39 levolansoprazole 2933.39 dabigatran 2933.39 lonafarnib 2933.39 dabigatran etexilate 2933.39 maraviroc 2933.39 dersalazine 2933.39 maropitant 2933.39 desloratadine 2933.39 miglustat 2933.39 dexlansoprazole 2933.39 minopafant 2933.39 dexmethylphenidate 2933.39 nerispirdine 2933.39 ecalcidene 2933.39 otamixaban 2933.39 elarofiban 2933.39 paliroden 2933.39 enzastaurin 2933.39 pipendoxifene 2933.39 esomeprazole 2933.39 prazarelix 2933.39 etoricoxib 2933.39 rimonabant 2933.39 ezlopitant 2933.39 rivanicline 2933.39 fidexaban 2933.39 senazodan 2933.39 gimeracil 2933.39 solimastat 2933.39 icaridin 2933.39 sorafenib 7 HS Subheading Description HS Subheading Description 2933.39 surinabant 2933.40 solifenacin 2933.39 tebanicline 2933.40 tafenoquine 2933.39 tecastemizole 2933.40 talnetant 2933.39 tenatoprazole 2933.40 tariquidar 2933.39 tesofensine 2933.40 torcetrapib 2933.39 ticalopride 2933.40 zelandopam 2933.39 timcodar 2933.40 zoniporide 2933.39 traxoprodil 2933.59 alamifovir 2933.39 varenicline 2933.59 albaconazole 2933.39 vatalanib 2933.59 ambrisentan 2933.39 vofopitant 2933.59 avanafil 2933.39 zanapezil 2933.59 balicatib 2933.40 alilusem 2933.59 cadrofloxacin 2933.40 gantacurium chloride 2933.59 caldaret 2933.40 garenoxacin 2933.59 dapivirine 2933.40 laniquidar 2933.59 darusentan 2933.40 meclinertant 2933.59 dasantafil 2933.40 olamufloxacin 2933.59 degarelix 2933.40 palosuran 2933.59 detiviciclovir 2933.40 pelitinib 2933.59 dofequidar 2933.40 pinokalant 2933.59 donitriptan 2933.40 pitavastatin 2933.59 emivirine 2933.40 pradofloxacin 2933.59 enecadin 2933.40 sitamaquine 2933.59 entecavir 8 HS Subheading Description HS Subheading Description 2933.59 erlotinib 2933.59 seliciclib 2933.59 esmirtazapine 2933.59 tandutinib 2933.59 etravirine 2933.59 tenofovir 2933.59 etriciguat 2933.59 tiviciclovir 2933.59 falnidamol 2933.59 valomaciclovir 2933.59 feloprentan 2933.59 vandetanib 2933.59 figopitant 2933.59 vestipitant 2933.59 forodesine 2933.59 zonampanel 2933.59 imatinib 2933.59 zosuquidar 2933.59 ispinesib 2933.69 bemotrizinol 2933.59 leteprinim 2933.69 eptapirone 2933.59 lopinavir 2933.69 oteracil 2933.59 midafotel 2933.69 ponazuril 2933.59 netupitant 2933.79 apixaban 2933.59 olcegepant 2933.79 bexlosteride 2933.59 omaciclovir 2933.79 brivaracetam 2933.59 pibrozelesin 2933.79 carmoterol 2933.59 plevitrexed 2933.79 cilengitide
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • E30 SEM. O.C. Disclosed Is a Compound Represented by the Formula (1) (51) Int
    USOO9453000B2 (12) United States Patent (10) Patent No.: US 9.453,000 B2 Kimura et al. (45) Date of Patent: *Sep. 27, 2016 (54) POLYCYCLIC COMPOUND (56) References Cited (75) Inventors: Teiji Kimura, Tsukuba (JP); Noritaka U.S. PATENT DOCUMENTS Kitazawa, Tsukuba (JP); Toshihiko 3,470,167 A 9, 1969 Sarkar Kaneko, Tsukuba (JP); Nobuaki Sato, 3,989,816 A 1 1/1976 Rajadhyaksha Tsukuba (JP); Koki Kawano, Tsukuba 4,910,200 A 3, 1990 Curtze et al. (JP): Koichi Ito, Tsukuba (JP); 5,281,626 A 1/1994 Oinuma et al. M s Tak ishi Tsukub JP 5,563,162 A 10, 1996 Oku et al. amoru Takaishi Tsukuba (JP); 5,804,577 A 9, 1998 Hebeisen et al. Takeo Sasaki, Tsukuba (JP); Yu 5,985,856 A 11/1999 Stella et al. Yoshida, Tsukuba (JP); Toshiyuki 6,235,728 B1 5, 2001 Golik et al. Uemura, Tsukuba (JP); Takashi Doko, g R 1939. E. al. Its SE E. Shinmyo, 7,138.414 B2 11/2006 Schoenafingereatch et al. et al. sukuba (JP); Daiju Hasegawa, 7,300,936 B2 11/2007 Parker et al. Tsukuba (JP); Takehiko Miyagawa, 7,314,940 B2 1/2008 Graczyk et al. Hatfield (GB); Hiroaki Hagiwara, 7,618,960 B2 11/2009 Kimura et al. Tsukuba (JP) 7,667,041 B2 2/2010 Kimura et al. 7,687,640 B2 3/2010 Kimura et al. 7,713,993 B2 5/2010 Kimura et al. (73) Assignee: EISAI R&D MANAGEMENT CO., 7,737,141 B2 6/2010 Kimura et al. LTD., Tokyo (JP) 7,880,009 B2 2/2011 Kimura et al.
    [Show full text]
  • Endogenous Opioid Analgesia in Peripheral Tissues and the Clinical Implications for Pain Control
    REVIEW Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control Daniel Kapitzke1,2 Abstract: Opioid receptors are widely expressed in the central and peripheral nervous system Irina Vetter1,2 as well as in numerous nonneuronal tissues. Both animal models and human clinical data Peter J Cabot2 support the involvement of peripheral opioid receptors in analgesia, particularly in inflammation where both opioid receptor expression and efficacy are increased. Immune cells have been 1 These authors contributed equally β to this work. 2School of Pharmacy, shown to contain numerous opioid peptides such as -endorphin (END), met-enkephalin University of Queensland, 4072, (ENK), and dynorphin-A (DYN), although the predominant opioid peptide involved in immune- Australia cell mediated antinociception is thought to be END. These opioid-containing immune cells migrate to inflamed tissues during a complex process of recruitment by chemokines, adhesion, and extravasation. In these tissues, opioid peptide is released from the immune cells upon stimulation with corticotrophin-releasing factor (CRF), noradrenaline, and interleukin 1β (IL-1β), and the immune cells return to the local lymph node depleted of peptide. Consistent with this model, systemic immunosuppression may lead to impaired endogenous analgesia as competent immune cells are essential to achieve release of endogenous opioid peptides within inflamed tissue. A further level of complexity is added by the observation that exogenous opioids may impair immune cell function, although there is some evidence to suggest that endogenous opioid peptides do not share this immunosuppressive effect. Improving our understanding of endogenous opioid mechanisms will provide valuable insight towards the development of novel treatments for pain with improved side effect profiles.
    [Show full text]
  • HIV-Infected Patients
    New Drugs for the Treatment-Experienced Patient Joseph Eron, md Associate Professor of Medicine and Director, Clinical Core unc Center for aids Research, University of North Carolina at Chapel Hill Summary by Tim Horn Edited by Jay Dobkin, md; Michael Saag, md reatment options for antiretro- humans by adenosine deaminase into D- Deeks and his colleagues in 1998 demon- viral-experienced patients leave a dioxolane guanine (dxg), a metabolite that strated a 1 log reduction in hiv-rna in hiv- lot to be desired. According to Dr. has potent activity against hiv and hbv. infected patients—more than 50% of whom Joe Eron, patients who have treat- According to in vitro data presented at were treatment-experienced—who received ment experience in all three classes the 3rd International Workshop on hiv tenofovir df 300 mg once daily as of currently available antiretrovi- Drug Resistance and Treatment Strategies, monotherapy for 28 days (Deeks, 1998). Trals have, at best, a 30% chance of re- held in June 1999, dapd was found to in- According to in vitro data presented by ducing their viral load to levels below 400 hibit wild-type and mutant isolates resistant Gilead’s Dr. Michael Miller at the recent copies/mL upon initiating a salvage regi- to azt (Retrovir) and 3TC (Borroto-Esoda, 4th International Resistance Workshop, the men. Cross-resistance within each class of 1999). The drug was also reported to be ac- resistance pattern for tenofovir df is simi- drugs, particularly the protease inhibitors tive against strains collected from patients lar to that of its chemical predecessor adefo- (pis) and non-nucleoside reverse tran- who have failed various nrti and nnrti vir, a compound no longer in development scriptase inhibitors (nnrtis), essentially combination therapies, including those for the treatment of hiv (Miller, 2000).
    [Show full text]
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • World Journal of Pharmaceutical Research Sonam Et Al
    World Journal of Pharmaceutical Research Sonam et al . World Journal of Pharmaceutical SJIF ImpactResearch Factor 5.990 Volume 4, Issue 8, 2393-2402. Review Article ISSN 2277– 7105 5-α-REDUCTASE INHIBITORS - A REVIEW Sonam Kaushal* and Manish Sinha Department of Pharmaceutical Chemistry, ASBASJSM College, Bela, Ropar, India. ABSTRACT Article Received on 19 June 2015, 5-alpha reductase is an important enzyme in metabolic pathway of Revised on 10 July 2015, testosterone. Its three subtypes SRD5A1, SRD5A2 andSRD5A3 are Accepted on 02 Aug 2015 responsible for conversion of testosterone to its more potent derivative dihydrotestosterone (DHT). Excess production of DHT leads to *Correspondence prostate cancer and alopecia. The production of DTH can be reduced For Author by inhibiting the 5-alpha reductase enzyme. Several 5-alpha reductase Sonam Kaushal Department of inhibitors were synthesized in the past and are marketed and used for Pharmaceutical the treatment of prostate cancer and baldness. The dosing of these Chemistry, ASBASJSM drugs is between 1 to 5 mg/day. The low dosing of these drugs need College, Bela, Ropar, special attention on quality control and quantitative estimation of drug India. in formulation and biological fluids. The details of 5-alpha reductase inhibitors and the recent developments in their quantitative estimation have been compiled in the presented review. KEYWORDS: 5-α-reductae inhibitors, cancer, quantitative estimation. 1. INTRODUCTION 1. 5-α-Reductase[1, 2, 3] 1.1. 5-α-reductases, also known as 3-oxo-5α-steroid 4-dehydrogenases, are enzymes involved in steroid metabolism. They participate in 3 metabolic pathways: bile acid biosynthesis, androgen and estrogen metabolism.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Study Protocol: LPCN 1021-18-001
    Oral Testosterone Undecanoate Protocol No. LPCN 1021-18-001 Lipocine Inc. TU, LPCN 1021 675 Arapeen Drive, Suite 202 Salt Lake City, UT-84108 1.0 TITLE PAGE Clinical Study Protocol: LPCN 1021-18-001 Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men. Investigational Product : Testosterone Undecanoate (TU, LPCN 1021) Date of Protocol : 19 February 2019 FDA IND No. : 106476 Development Phase : Phase 3 Testosterone replacement therapy in adult, 18 years or older, males for conditions associated with a deficiency or absence of endogenous Indication : testosterone – primary hypogonadism (congenital or acquired) or secondary hypogonadism (congenital or acquired) Investigator : Multi-Center, US Sponsor : Lipocine Inc. 675 Arapeen Drive, Suite 202, Salt Lake City, Utah – 84108 Tel: +1-801-994-7383 Fax: +1-801-994-7388 Sponsor / : Nachiappan Chidambaram Emergency Contact 675 Arapeen Drive, Suite 202, Salt Lake City, Utah – 84108 Tel: +1-801-994-7383, Ext 2188 Fax: +1-801-994-7388 Email: [email protected] Protocol Version : 06 Confidentiality Statement This document is a confidential communication of Lipocine Inc. Acceptance of this document signifies agreement by the recipient that no unpublished information contained within will be published or disclosed to a third party without prior written approval, except that this document may be disclosed to an Institutional Review Board under the same conditions of confidentiality. Date: 19 February 2019 Confidential Page 1 of 50 Oral Testosterone Undecanoate Protocol No. LPCN 1021-18-001 Lipocine Inc. TU, LPCN 1021 675 Arapeen Drive, Suite 202 Salt Lake City, UT-84108 2.0 SUMMARY OF CHANGES TO PROTOCOL VERSION 2 Version 02 of the LPCN 1021-18-001 study protocol was developed to make the following changes to the study: • Added sexual desire and sexual distress questions to pre-treatment and post-treatment phases of the study.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis Et Al
    USOO949854.4B2 (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis et al. (45) Date of Patent: Nov. 22, 2016 (54) GENETICALLY MODIFIED HUMAN (56) References Cited UMIBILICAL CORD PERVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR U.S. PATENT DOCUMENTS TREATMENT OF BIOLOGICAL, OR 5,158,867 A 10/1992 McNally et al. CHEMICAL AGENTS 5,919,702 A 7/1999 Purchio et al. 6,132,724 A 10/2000 Blum (71) Applicant: Tissue Regeneration Therapeutics 7,122,178 B1 10/2006 Simmons et al. 7,547,546 B2 6/2009 Davies et al. Inc., Toronto (CA) 2003.0161818 A1 8, 2003 Weiss et al. 2004/O136967 A1 7/2004 Weiss et al. 2004/O137612 A1 7/2004 Baksh et al. (72) Inventors: Jane Elizabeth Ennis, Oakville (CA); 2005/OO 19911 A1 1/2005 Gronthos et al. Jeffrey Donald Turner, 2005, 0148074 A1 7/2005 Davies et al. Chute-a-Blondeau (CA); John Edward 2005/O158289 A1 7/2005 Simmons et al. Davies, Toronto (CA) 2005/0281790 A1 12/2005 Simmons et al. 2006, OOO8452 A1 1/2006 Simmons et al. 2006, O193840 A1 8, 2006 Gronthos et al. (73) Assignee: Tissue Regeneration Therapeutics 2006, O199263 A1 9/2006 Auger et al. Inc., Toronto (CA) 2006/0286O77 A1 12/2006 Gronthos et al. 2007/0134205 A1 6/2007 Rosenberg 2008.0020459 A1 1/2008 Baksh et al. (*) Notice: Subject to any disclaimer, the term of this 2008.0113434 A1 5/2008 Davies et al. patent is extended or adjusted under 35 2009/0047277 A1 2/2009 Reed et al.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]